1. Screening and evaluation of human intestinal lactobacilli for the development of novel gastrointestinal probiotics.
- Author
-
Kõll P, Mändar R, Smidt I, Hütt P, Truusalu K, Mikelsaar RH, Shchepetova J, Krogh-Andersen K, Marcotte H, Hammarström L, and Mikelsaar M
- Subjects
- Acids toxicity, Animals, Anti-Bacterial Agents toxicity, Bacterial Translocation, Bile metabolism, DNA, Bacterial chemistry, DNA, Bacterial genetics, Erythrocytes microbiology, Hemolysis, Humans, Hydrogen-Ion Concentration, Lactobacillus classification, Lactobacillus drug effects, Lactobacillus growth & development, Mice, Mice, Inbred BALB C, Microbial Viability drug effects, Molecular Sequence Data, Pancreatin toxicity, Sequence Analysis, DNA, Lactobacillus physiology, Probiotics
- Abstract
The aim of this study was to screen intestinal lactobacilli strains for their advantageous properties to select those that could be used for the development of novel gastrointestinal probiotics. Ninety-three isolates were subjected to screening procedures. Fifty-nine percent of the examined lactobacilli showed the ability to auto-aggregate, 97% tolerated a high concentration of bile (2% w/v), 50% survived for 4 h at pH 3.0, and all strains were unaffected by a high concentration of pancreatin (0.5% w/v). One Lactobacillus buchneri strain was resistant to tetracycline. None of the tested strains caused lysis of human erythrocytes. Six potential probiotic strains were selected for safety evaluation in a mouse model. Five of 6 strains caused no translocation, and were considered safe. In conclusion, several strains belonging to different species and fermentation groups were found that have properties required for a potential probiotic strain. This study was the first phase of a multi-phase study aimed to develop a novel, safe and efficient prophylactic and therapeutic treatment system against gastrointestinal infections using genetically modified probiotic lactobacilli.
- Published
- 2010
- Full Text
- View/download PDF